Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
article
Minesoft’s Chemical Explorer helps users to find chemical information in patents issued by multiple authorities. Robert Poolman explains how it works.   2 June 2016
Americas
Pay-for-delay agreements, otherwise known as reverse settlements, stand at the intersection of intellectual property and competition law, but the clarity hoped for after Actavis has not yet arrived. LSIPR investigates.   1 June 2016
Big Pharma
Despite several major EU rulings on supplementary protection certificates, national IP offices and courts can form differing interpretations, and it seems that a unitary-style SPC right would be hard to create. LSIPR reports.   1 June 2016
Americas
In 2015 the US Federal Circuit resolved the biosimilars case of Amgen v Sandoz. But the parties did not stop there, meaning the Supreme Court could potentially review it. LSIPR looks at the consequences of a possible review.   31 May 2016
Americas
A firm advocate of ‘open innovation’, Novartis is setting aside rivalries and working on a number of projects to ensure patients get the best treatments as quickly as possible. LSIPR spoke to Graham Stuart of the company about some of the work.   31 May 2016
Americas
Each ‘patent dance’ dispute between biologics and biosimilars companies will present its own nuances in the process of solving the mystery, argue Lisa Pensabene and Daniel O'Boyle of O’Melveny & Myers.   26 May 2016
Africa
It is likely that many patent applications directed to CRISPR technology will be filed in India, says Hemant Singh of Inttl Advocare, who analyses some of the early applications and the rules on patentability.   19 May 2016
Big Pharma
There is a lack of judicial guidance in Europe on the issue of third party supplementary protection certificates (SPCs), otherwise known as “SPC squatting”, as Trevor Cook of WilmerHale explains.   12 May 2016
Americas
CRISPR is only part of the gene editing story, and by studying the patents associated with all of the various methods, a much clearer picture of the entire field can be generated, says Tony Trippe, senior patent analyst for Thomson Reuters.   5 May 2016
Africa
Ahead of the English Court of Appeal’s hearing in May in the Warner-Lambert case on second medical use patents, Charlotte Weekes and Tamsin Cornwell of Pinsent Masons examine some of the unanswered questions.   28 April 2016